The association of the adiponectin/leptin ratio with adipose tissue dysfunction and metabolic diseases were described [123], and current findings in COVID-19 disease encourage prospective studies to further evaluate this ratio as a clinical relevant indicator. This evidence concerns the gene LEP and metabolic disease.